SVP Revenue   |   UK/EU   |   28th June 2022

Reliance Health appoint Olivier Nairey as SVP Revenue


Renaissance are pleased to announce the appointment of Olivier Nairey as SVP Revenue at Reliance Health

Founded in 2016 by Femi Kuti, Opeyemi Olumekun, and Matthew Mayaki, Reliance Health is on a mission to make quality healthcare accessible and affordable in countries where the dominant path to healthcare has been to pay at the point of access. Reliance Health uses technology and data science to build an integrated health system that includes affordable health insurance, telemedicine and a combination of partner and proprietary healthcare facilities. This allows them to offer innovative healthcare solutions that meet the needs of customers in emerging markets.

Reliance received an early injection of funding from Partech Partners, Y Combinator and Tencent. The business announced a subsequent $40m Series B round, led by General Atlantic, in February of this year. In line with their international expansion model, they have made the following hire to their executive leadership team:

Olivier Nairey – SVP Revenue

Olivier joins Reliance Health from TravelPerk, where he held the role of VP Sales for EMEA. TravelPerk is a B2B travel platform that enables companies to get the most out of their employees’ travel through a suite of booking and expense management services.

Olivier has a multinational sales background, with a strong track record of sales success in growth-stage businesses. The team at Reliance were impressed by Olivier’s mission-focused approach and deep knowledge and affinity for emerging markets.

Olivier has joined to provide clarity, vision and commercial leadership as Reliance Health expand their services internationally; boosting sales efficiency, ensuring that new country launches are successful, whilst also implementing a strategic long-term vision for future growth.

For more information, please visit


Assignment conducted by:

Keep up-to-date

Sign up to receive our regular updates and newsletters, and see more of what we've been working on.